Regenxbio (RGNX) Research & Development (2014 - 2026)
Regenxbio (RGNX) reported Research & Development of $56.09 million for Q2 2026, down 5.7% from $59.5 million a year earlier.
Powered by 
Analysis
Regenxbio (RGNX) Research & Development (2014 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Regenxbio's Research & Development came in at $231.3 million, up 6.4% year-over-year; for FY2025, it came in at $228.3 million, up 9.5% from FY2024.
- Research & Development has a five-year compound annual growth rate of 6.5% (FY2020 to FY2025).
- By year, Research & Development came in at $208.52 million in FY2024 (-10.2%), $232.27 million in FY2023 (-4.2%), $242.45 million in FY2022 (+33.6%) and $181.44 million in FY2021 (+9.1%).
- The Q2 2026 figure ranks as the lowest quarterly Research & Development since Q1 2025.
- Year over year, Research & Development gained in three of the last seven quarters, with growth averaging 2.6%.
- The high point for year-over-year Research & Development in five years was Q1 2022 (growth of 40.0%); the low point was Q2 2024 (a decline of 18.4%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,147.31 Bn | 1,115.89 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 624.29 Bn | 542.81 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 511.65 Bn | 484.76 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 365.71 Bn | 320.09 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.61 Bn | 261.60 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.35 Bn | 235.03 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 234.89 Bn | 190.29 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 194.41 Bn | 168.60 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 172.08 Bn | 118.73 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Regenxbio | 396.41 Mn | -536.68 Mn | - | 56.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 56.09 Mn |
| Dec 31, 2025 | 59.61 Mn |
| Sep 30, 2025 | 56.10 Mn |
| Jun 30, 2025 | 59.50 Mn |
| Mar 31, 2025 | 53.09 Mn |
| Dec 31, 2024 | 50.38 Mn |
| Sep 30, 2024 | 54.43 Mn |
| Jun 30, 2024 | 48.87 Mn |
| Mar 31, 2024 | 54.84 Mn |
| Dec 31, 2023 | 55.68 Mn |
| Sep 30, 2023 | 58.18 Mn |
| Jun 30, 2023 | 59.89 Mn |
| Mar 31, 2023 | 58.52 Mn |
| Dec 31, 2022 | 62.51 Mn |
| Sep 30, 2022 | 63.31 Mn |
| Jun 30, 2022 | 61.01 Mn |
| Mar 31, 2022 | 55.63 Mn |
| Dec 31, 2021 | 47.98 Mn |
| Sep 30, 2021 | 47.86 Mn |
| Jun 30, 2021 | 45.88 Mn |
API Access
Regenxbio Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=RGNX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "RGNX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=RGNX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();